Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus  by Smith, Gale E. et al.
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The  recent  emergence  of severe  human  illness  caused  by avian-origin  inﬂuenza  A(H7N9)  viruses  in China
has  precipitated  a  global  effort  to rapidly  develop  and  test  vaccine  candidates.  To  date,  non-A(H7N9)  H7
subtype  inﬂuenza  vaccine  candidates  have  been  poorly  immunogenic  and  difﬁculties  in production  of
A(H7N9)  virus  seed  strains  have  been  encountered.  A  candidate  recombinant  A(H7N9)  vaccine  consisting
of  full  length,  unmodiﬁed  hemagglutinin  (HA)  and  neuraminidase  (NA)  from  the A/Anhui/1/2013  and  the
matrix  1  (M1)  protein  from  the  A/Indonesia/05/2005  (H5N1)  were  cloned  into  a baculovirus  vector.  Bac-
ulovirus  infected  Spodoptera  frugiperda  (Sf9)  insect  cells  secreted  virus  like  particles  (VLP)  composed  of
HA,  NA,  and  M1 that resemble  mature  inﬂuenza  virions.  Genetic  construction  of  vaccine  from  acquisition
of  an  H7N9  genomic  sequence  to production  of  A(H7N9)  VLP  occurred  in  26  days.  The  immunogenicity
and  efﬁcacy  of A/Anhui/1/2013  (H7N9)  VLP vaccine  administered  on days  0  and  14  were  evaluated  in  a
lethal  wild-type  challenge  Balb/c  mouse  model.  Control  groups  included  a non-homologous  H7 vaccine
(A/chicken/Jalisco/CPA1/2012  (H7N3)-VLP),  and  A/Indonesia/05/2005  (H5N1)-VLP,  or  placebo.  All  vac-
cines  were  administered  with  or without  ISCOMATRIX.  A(H7N9)  VLP  elicited  hemagglutination-inhibition
(HAI) antibody  titers of  ≥1:64  against  the  homologous  virus,  cross-reactive  HAI against  the  heterologous
A(H7N3),  and  3-  to 4-fold  higher  HAI  responses  in  corresponding  ISCOMATRIX  subgroups.  Similarly,  all
doses  of H7N9  VLP  elicited  anti-neuraminidase  (NA)  antibody,  with 3- to  4-fold  higher  responses  mea-
sured  in the corresponding  ISCOMATRIX  subgroups.  The  non-homologous  H7  vaccine  induced  both  H7N3
and  H7N9  HAI  but no  N9  anti-NA  antibodies.  A  lethal  murine  wild-type  A/Anhui/1/2013  (H7N9)  challenge
demonstrated  100%  survival  of all animals  receiving  A(H7N9)  and A(H7N3)  vaccine,  versus  0%  survival
in  A(H5N1)  vaccine  and  placebo  groups.  Together,  the  data  demonstrate  that  recombinant  H7N9  vaccine
can  be  rapidly  developed  that was  immunogenic  and  efﬁcacious  supporting  testing  in  man  as  a  pandemic
inﬂuenza  H7N9  vaccine  candidate.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Following recognition of the ﬁrst human infections with
vian-origin inﬂuenza A(H7N9) and their attendant severity in
arch 2013, public health ofﬁcials from around the world have
alled for immediate and preemptive development of surveillance,
     
∗ Corresponding author. Tel.: +1 240 268 2000x2027; fax: +1 240 268 2127.
E-mail address: gsmith@novavax.com (G.E. Smith).
264-410X ©  2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2013.07.043
Open access under CC BY-NC-NDdiagnostic and clinical intervention tools in the event that these
viruses become readily transmissible among humans [1–3]. The
Arg292Lys mutation in the virus neuraminidase (NA) gene known
to confer resistance to both zanamivir and oseltamivir has already
been identiﬁed in two  patients [4], which places further pressure
on the development and clinical testing of candidate vaccines.
Nearly  all inﬂuenza vaccines commercially distributed in the
world today are conventional inactivated “split” or subunit vac-
cines that require a vaccine virus that grows well enough in eggs
or cultured mammalian cells to produce sufﬁcient amounts of
the essential vaccine antigen, hemagglutinin (HA). This process
is iterative and often time-consuming, and occasionally requires
selection of an HA that is less than optimally matched to the HA of
 license.
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redominantly circulating strains [5]. The development of recom-
inant HA-based vaccines offer the potential for overcoming
hese limitations [6], but some observers remain concerned that
A-based vaccines could be inadequately effective, especially in
ulnerable populations such as the elderly, who appear to be a
ritical target population for A(H7N9)-mediated severe disease [7].
An A(H7N9) vaccine candidate was constructed from full length,
nmodiﬁed inﬂuenza hemagglutinin (HA) and neuraminidase (NA)
rom the A/Anhui/1/2013 strain and the matrix 1 (M1) protein
rom the A/Indonesia/05/2005 (H5N1) strain. The corresponding
enes were cloned into a baculovirus expression vector to pro-
uce A(H7N9) VLP in Spodoptera frugiperda (Sf9) insect cells. The
xpressed HA, NA, and M1  self-assembled into virus-like parti-
les (VLP) and were secreted as enveloped, pleomorphic particles
hat resemble live, mature inﬂuenza virions. Previous VLP vac-
ine candidates developed for H1N1, H3N2, B strains and H5N1
ave been shown to display conformational-dependent antigenic
pitopes associated with HA oligomers and have induced robust
nti-HA and anti-NA antibody responses in clinical studies in over
000 subjects [8,9].
In  this report, we describe the rapid development of an
/Anhui/1/2013 (H7N9) vaccine candidate and accompanying
otency reagents. The immunogenicity, efﬁcacy, and induction of
ross-protective antibodies in immunized mice challenged with a
ethal dose of A/Anhui/1/2013 inﬂuenza virus following immuniza-
ion with VLPs representing homologous A(H7N9), heterologous
(H7N3), and a control A(H5N1) with and without the saponin-
ased ISCOMATRIX are described.
. Materials and methods
.1.  Recombinant baculovirus and insect cells
The HA and NA protein sequences of inﬂuenza A/Anhui/1/2013
H7N9) were obtained from GISAID Epiﬂu database
www.gisaid.org) with accession number EPI439507 and
PI439509,  respectively. A/Shanghai/1/2013 (H7N9) HA and
A were obtained from GISAID Epiﬂu database with accession
umber EPI439486 and EPI439487, respectively. The HA and NA
rotein sequences of A/chicken/Jalisco/CPA1/2012(H7N3) were
btained from NCBI GenBank with accession number AFN85519
nd AFN70735, respectively. The HA, NA and M1  protein sequences
f A/Indonesia/05/2005 (H5N1) were from NCBI GenBank with
ccession number ABP51969, ABW06107 and ABI36004, respec-
ively. The genes were codon optimized for optimal expression in
nsect cells and biochemically synthesized for A(H5N1) HA, NA, M1
Geneart AG, Regensburg, Germany); and for A(H7N9) and A(H7N3)
A and NA genes (Genscript, Piscataway, NJ). Inﬂuenza VLP were
roduced using full length, HA and NA genes speciﬁc for each
train combined with common inﬂuenza A/Indonesia/05/2005 M1
s described [10,11]. Full length HA, NA, and M1  genes were cloned
etween BamHI–HindIII sites in pFastBac1 baculovirus transfer
ector plasmid (Invitrogen, Carlsbad, CA) such that each gene was
nder the transcriptional control of the Autographa californica mul-
iple nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter.
ecombinant baculovirus construct was plaque puriﬁed and
aster seed stocks prepared, characterized for identity, and used
o prepare working virus stocks. The titers of baculovirus master
nd working stocks were determined by using rapid titration kit
BacPak Baculovirus Rapid Titer Kit; Clontech, Mountain View, CA).
S. frugiperda Sf9 insect cells (ATCC CRL-1711) were maintained
s suspension cultures in HyQ-SFX insect serum free medium
HyClone, Logan, UT) at 27 ± 2 ◦C. Recombinant baculovirus stocks
ere prepared by infecting cells at a low multiplicity of infection
MOI) of ≤0.01 plaque forming units (pfu) per cell and harvested at
8–72 h post infection (hpi).1 (2013) 4305– 4313
2.2.  Recombinant inﬂuenza VLP, HA, and NA
A(H7N9), A(H7N3), and A(H5N1) VLP and inﬂuenza A(H7N9) HA
and NA antigens were produced in Sf9 cells at 2–3 × 106 cells/ml
infected with speciﬁc recombinant baculovirus. Infected Sf9 cells
were incubated with continuous agitation at 27 ± 2 ◦C and har-
vested at 68–72 hpi by centrifugation at 4000 × g for 15 min. VLP
were puriﬁed from the infected cell media. Brieﬂy, media contain-
ing VLP and baculovirus particles was concentrated and dialyzed
against buffer using hollow ﬁber tangential ﬂow ﬁltration. Sepa-
ration of VLP from baculovirus and other host contaminants was
done using anion exchange followed by gel ﬁltration chromatog-
raphy. Puriﬁed VLP in phosphate buffered saline were 0.2 micron
ﬁltered and stored at 2–8 ◦C.
Full  length A(H7N9) HA and NA glycoproteins were produced
in Sf9 cells as described above. Recombinant HA and NA were
extracted from cellular membranes with 25 mM Tris-Cl (pH 8.0),
50 mM NaCl, 0.5% Tergitol NP9 and 2 g/ml Leupeptin and insol-
uble material removed by centrifugation at 10,000 × g for 30 min.
HA and NA oligomers were puriﬁed using a combination of anion
exchange, lectin afﬁnity and cation exchange chromatography.
During puriﬁcation the detergent is removed allowing HA  trimers
and NA tetramers to form higher ordered protein-protein micellu-
lar nanoparticles. Puriﬁed, detergent-free NA and HA nanoparticles
were 0.2 m ﬁltered and stored at −80 ◦C.
2.3. Analytical methods
H7N9  HA, NA and VLP were analyzed by SDS-PAGE using 4–12%
gradient polyacrylamide gels (Invitrogen), stained with GelCode
Blue stain reagent (Pierce, Rockford, IL) and quantiﬁed by scanning
densitometry using OneDscan system (BD Biosciences, Rockville,
MD). Puriﬁed A(H7N9), A(H7N3), and A(H5N1) VLP were tested for
total protein concentration (BCA bicinchoninic acid protein assay,
Pierce Biochemicals) and particle size by dynamic light scattering
using ZETASizer Nano (Malvern Instruments, PA) using standard
manufacturer recommended methods.
To identify the major proteins in puriﬁed A(H7N9) NA
and HA, samples were tested by peptide mapping and liquid
chromatography–mass spectrometry (LC–MS). 50 L of NA or HA
were mixed with 100 L 25 mM ammonium bicarbonate contain-
ing 0.08% RapiGest and 4 L of 250 mM DDT solution and heated
at 60 ◦C for 30 min. After cooling to room temperature (RT), 8 L
of 250 mM iodoacetamide was  added and incubated at room tem-
perature in the dark for 30 min. 10 L of 1 g/L trypsin solution
was added to digest the sample for 5 h at 37 ◦C. The digested
samples were incubated for 20 min, followed by centrifugation at
20,000 × g for 20 min, and LC–MS analysis performed on an Agilent
1200 system (Agilent, Santa Clara, California). Protome Discover
1.3 software (Thermo Scientiﬁc, Logan, UT) was used for database
searching of a custom protein database including sequences for
baculovirus, insect cells, and inﬂuenza genes.
Capillary gel electrophoresis (CE) was carried out using a Beck-
man PA 800 plus Pharmaceutical Analysis System equipped with an
untreated fused-silica capillary of 60 cm,  375 mm I.D. detector at a
UV absorbance of 220 nm.  Prior to each run, the capillary is regen-
erated by base and acid wash then rinsed with water and reﬁlled
with buffer before each sample injection. Electrophoretic separa-
tions were carried out at a constant voltage of 30 K volts for 30 min.
32 Karat software from the manufacturer was  used to process data.
Sample buffer was 1% SDS, 10% -mercaptoethanol, 100 mM Tris
and 1 L of P10KD marker per 50 L of sample. A(H7N9) VLP sam-
ple was  mixed 1:1 with sample buffer and incubated at 70 ◦C for
10 min  to denature and reduce VLP proteins. Denatured samples
were incubated with Triton X-100 and PNGase F for >2 h at 37 ◦C to
remove N-linked glycans prior to analysis. A P10KD marker was
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sed as internal standard to align peaks from different electro-
herograms.
.4. Inﬂuenza viruses
The  A/Anhui/1/2013 (H7N9) virus was kindly obtained from
odd Davis, Ph.D., Team Lead, Zoonotic Virus Team, Inﬂuenza Divi-
ion, CDC, Atlanta, GA. The wild-type A/Anhui/1/2013 (H7N9) virus
tock was produced (BIOQUAL, Inc., Rockville, MD)  by inoculating
0-day old embryonated hens eggs with a A/Anhui/1/2013 (H7N9)
eed virus CDC #2013759189 (Centers for Disease Control, Atlanta,
A). A/Anhui/1/2013 (H7N9) virus had an infectious titer of 107.95
issue culture infectious doses/ml (TCID50) in Madin Darby canine
idney cells (MDCK) and a 50% lethal dose (LD50) in adult female
ALB/c mice of 1200 TCID50/ml.
.5. Electron microscopy
A(H7N9)  puriﬁed VLP were adsorbed by ﬂotation for 2 min  onto
 freshly discharged 400 mesh carbon parlodion-coated copper grid
Poly-Sciences, Warrington, PA). The grids were rinsed with buffer
ontaining 20 mM Tris, pH 7.4, and 120 mM KCl and negatively
tained with 1% phosphotungstic acid, then dried by aspiration.
irus-like particles were visualized on a Hitachi H-7600 trans-
ission electron microscope (Hitachi High Technologies America,
chaumburg, IL) operating at 80 kV and digitally captured with
 CCD camera at 1K × 1K resolution (Advanced Microscopy Tech-
iques Corp., Danvers, MA).
.6. Immunological assays
Individual  sera were tested for HAI titers against
/Anhui/1/2013 (H7N9) inﬂuenza virus, A/Indonesia/05/2005
H5N1), A/chicken/Jalisco/CPA1/2012 (H7N3) and A/Shanghai/
/2013 (H7N9) VLP. Sere were treated with receptor destroying
nzyme (RDE) at 37 ◦C overnight. The following day, RDE was
nactivated by incubation at 56 ◦C for 1 h. Individual mouse sera
25 L) were serially diluted (starting at an initial sample dilution
f 1:10) and incubated with 4-HA units of inﬂuenza virus or VLP in
5 L. Fresh horse red blood cells (0.75%) (Lampire, Pipersville, PA)
ere added to the virus for one hour. Red cell agglutination status
as determined at the end of the incubation period. The HAI titer
as deﬁned as the reciprocal titer at which no agglutination was
bserved. The lower limit of quantitation for the assay was 10;
iters lower than 10 were considered to be negative and assigned
 value of 5.
Neuraminidase inhibiting (NI) antibody titers were determined
n an enzyme-linked lectin assay using peroxidase-labeled peanut
gglutinin (PNA-PO; Sigma, St Louis, MO)  to bind to desialylated
etuin. NA activity was determined by incubating serial dilutions
f puriﬁed, full length A(H7N9) NA on fetuin coated microtiter
lates. The use of puriﬁed NA eliminated HA which can inter-
ere in a fetuin-based NI assay. After 30 min  incubation at RT,
lates were washed and PNA-PO added. After 1 h incubation at RT,
lates were again washed and the peroxidase substrate 3,3′,5,5′-
etramethylbenzidine added and color development allowed to
roceed for 10 min. Color development was stopped and the plates
he OD450 measured using a SpectraMax plus plate reader (Molec-
lar Devices, Sunnyvale. CA). Data were plotted as a 4-parameter-ﬁt
lot and the dilution corresponding to 95% NA activity determined.
NI titers against A(H7N9), A(H7N3), and A(H5N1) were mea-
ured beginning at a 1:20 dilution of mouse sera followed by 2-fold
erial dilutions in 96-well U-bottomed tissue culture plates. NAs
orresponding to 95% maximum activity were added to diluted
era and incubated for 30 min  at RT after which sera/NA samples
ere transferred to fetuin coated microtiter plates. Plates were1 (2013) 4305– 4313 4307
incubated  for 2 h at 37 ◦C, washed and PNA-PO added. The plates
incubated at RT an additional hour, washed and peroxidase sub-
strate TMB  added. Color development was stopped after 10 min
and the OD450 of the plates measured using a SpectraMax Plus
plate reader (Molecular Devices, LLC, and Sunnyvale, CA). The data
were analyzed using the manufacture’s SoftMax software and NI
titers deﬁned as the reciprocal dilution at which 50% NA activity
was inhibited. The lower limit of quantitation for the assay was  20;
titers lower than 20 were considered to be negative and assigned a
value of 10.
2.7.  Mouse immunization and challenge
Balb/c mice (6–8 weeks old) were purchased from Harlan Lab-
oratories, Inc. (Fredrick, MD). Mice (8 per group) were immunized
intramuscularly days 0 and 14 in the quadriceps muscles with
A/Anhui/1/2013 (H7N9), A/chicken/Jalisco/CPA1/2012 (H7N3), or
A/Indonesia/05/2005 (H5N1) VLP (0.6–6 g based on HA content)
with and without 1.9 ISCOTM units (IU) of ISCOMATRIXTM adjuvant
(ISCOMATRIX; CSL Biotherapies Inc., King of Prussia, Pennsylvania,
USA; ISCOMATRIX is a registered trademark of ISCOTEC Ab a CSL
company; ISCO is a registered trademark of CSL). Immunizations
were done on day 1 and 14 and serum sera collected on day 0 and
21 for serological analysis. Blood was collected via the retro-orbital
route and serum was  obtained by centrifugation of whole blood.
Mice  were transferred to a biological safety level 3 (BSL3) facility
for inﬂuenza challenge. Inﬂuenza A/Anhui/1/2013 virus challenge
with 4.4 × 103 TCID50 pfu (equal to 3.6 × LD50) was  performed on
day 22. Prior to virus instillation, mice were anaesthetized with
intra-peritoneal (IP) injection of a ketamine (125 mg/kg)/xylazine
(2.5 mg/kg) HCl solution. The mice were then positioned on their
back and 25 L virus solution delivered drop-wise into each nostril.
After challenge, the animals were observed for signs of illness and
weighed daily for 14 days to assess morbidity. Mice identiﬁed as
moribund or having lost >25% of body weight were euthanized.
On  day 3 post challenge three animals per group were eutha-
nized and lung tissue collected for virus isolation. Lung tissue was
weighed and frozen. Cryopreserved lungs were quickly thawed and
homogenized in 0.5 mL  cold medium (DMEM/10% FBS/gentamicin)
for approximately 20 s using a hand-held tissue homogenizer
(Omni International, Kennesaw, GA), and spun down to remove
debris. The resultant supernatant was added in 10-fold graded dilu-
tions to MDCK (Madin-Darby canine kidney) cells (ATCC, Manassas,
VA) monolayers in 96-well tissue culture plates. Speciﬁcally, the
supernatant was added to the ﬁrst row of wells (10 L/well) of
a 96-well tissue culture plate and then diluted 10-fold (6 wells
per dilution) for a total of 6 dilutions. The ﬁrst well represented
a 1:10 dilution of the sample. The plates were incubated at 37 ◦C
for a 2-day period. Fifty (50) L from each well was  transferred to
a 96-well V-bottomed plate and 50 L 0.5% Turkey RBC (Lampire,
Pipersville, PA) in PBS added to each well. The hemagglutination
pattern was  read following 30 min at RT. The Reed–Muench for-
mula was  applied to calculate virus titer and was expressed as log10
TCID50/g of tissue.
All  animal procedures were in accordance with the NRC Guide
for the Care and Use of Laboratory Animals, the Animal Welfare
Act, and the CDC/NIH Biosafety in Microbiological and Biomedical
Laboratories.
2.8. Statistical analysis
Statistical  analyses were performed using SAS® version 9.1.3
in a Windows environment (SAS Institute Inc., Cary, NC, USA).
Antigen-speciﬁc antibody response as measured by neutralizing
antibody to HA and NA. Results were summarized using the geo-
metric mean titer (GMT) and corresponding 95% CI.
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Differences in GMTs among vaccine groups were analyzed using
n ANOVA model with ﬁxed effects for vaccine group. Modeling
as performed using PROC MIXED in SAS with data from Day 21.
he data at Day 21 were log10-transformed prior to statistical anal-
sis. The overall treatment difference was assessed using global
-test. Pairwise comparisons of vaccine groups was  analyzed and
stimated by least squares mean (LSMEANS) at Day 21 adjusted by
ukey. A p-value <0.05 was considered signiﬁcant for vaccine group
omparisons.
. Results
.1. Inﬂuenza A(H7N9) HA, NA, and VLP
Baculovirus vectors were constructed to express
/Anhui/1/2013 (H7N9), A/chicken/Jalisco/CPA1/2012 (H7N3),
nd A/Indonesia/05/2005 (H5N1) VLP with HA, NA, and M1  genes
n tandem such that each were ﬂanked with a 5′-AcMNPV poly-
edrin promoter (PolH), 3′-polyadenylation signal (pA), with a 5′
o 3′ order of NA, M1,  and HA (Fig. 1A). A/Anhui/1/2013 (H7N9) HA
nd NA were also expressed in separate baculovirus vectors.
Puriﬁed  A(H7N9) NA and HA; and A(H7N9), A(H7N3), and
(H5N1) VLP were analyzed by SDS-PAGE and stained with
oomassie blue (Fig. 1B; left panel). At the time of the analysis,
o speciﬁc A(H7N9) antibodies were available for identiﬁca-
ion. However, a mouse monoclonal antibody against another H7
ubtype, A/Netherlands/219/2003 (H7N7) (SinoBiological, Beijing,
hina), did recognize A(H7N9) and A(H7N3) HAs in a West-
rn blot (Fig. 2B; second panel Western blot). To identify NAs,
 rabbit antibody against a conserved NA peptide ILRTQESEC
eacted strongly with A(H7N9) NA and VLPs as well as NA in
oth A(H7N3) and A(H5N1) VLP (Fig. 1B, third panel Western
lot). Sheep anti A(H5N1) HA recognized only the homologous
5 hemagglutinin (Fig. 1B, forth panel Western blot). The major
roteins in puriﬁed A(H7N9), A(H7N3), and A(H5N1) VLP prepa-
ations were HA and M1  with less but detectable NA (Fig. 1B).
aculoviruses were not completely removed but major struc-
ural nucleocapsid proteins vp39 and p6.9 were not detectable by
DS-PAGE (Fig. 1B). The major baculovirus envelop glycoprotein
p64 was separated from HA by CE electrophoresis and estimated
o be about 5% of the total protein in puriﬁed VLPs (data not
hown).
To conﬁrm the identity of A/Anhui/1/2013 (H7N9) HA and NA,
C–MS analysis was performed with puriﬁed antigens. Over 70%
f the A/Anhui/1/2013 HA and NA were identiﬁed as having the
xpected amino acid sequences, conﬁrming their identity.
HA  and NA antigens in A(H7N9) and A(H7N3) VLP essentially co-
igrate by SDS-PAGE limiting the use of scanning densitometry
o estimate the HA concentration and thus the dose for immu-
ization. However, capillary gel electrophoresis of deglycosylated
(H7N9) VLP resolved HA and NA with a single sharp deglyco-
ylated HA peak and a leading smaller deglycosylated NA peak
Fig. 1C). The identity of M1 and PNGase F related peaks were also
dentiﬁed (Fig. 1C). The percentage of each peak was  calculated
ased on each peak area divided by total peak area with PNGase F
nd P10KD marker related peaks excluded. Peak area was  corrected
y velocity by the software. The average of triplicate measurements
howed 28.5% HA and 5.1% NA of total protein in puriﬁed A(H7N9)
LP.
Transmission electron microscopy of puriﬁed A/Anhui/1/2013H7N9) VLP was consistent with a size of about 150 nm measured
sing dynamic light scattering (Fig. 1D). The A(H7N9) VLP were
argely spherical, pleomorphic, enveloped and with a high density
f protein spikes presumed to be HA and NA oligomers projecting
rom the surface of each particle.1 (2013) 4305– 4313
3.2.  Immunogenicity of inﬂuenza A(H7N9), A(H7N3), and
A(H5N1)  VLP
BALB/c  mice were immunized with 0.7, 2 and 6 g of inﬂuenza
A(H7N9) VLP, 0. 7 and 2 g of A(H7N3) VLP or 1 and 3 g of
A(H5N1) VLP vaccines (based on HA content and corrected for
%HA based on capillary electrophoresis) on days 0 (prime) and 14
(boost) and serum samples were obtained on day 0 and 21 for the
measurement of antibody responses. Anti-HA responses were eval-
uated in HAI assays using A/Anhui/1/2013 (H7N9) virus (Fig. 2A),
A(H7N9) VLP derived from A/Shanghi/1/2013 virus (Fig. 2B),
and A(H7N3) VLP derived from A/chicken/Jalisco/CPA1/2012 virus
(Fig. 2C). VLP were used in H7N9 A/Shanghai/1/2013 and H7N3
A/chicken/Jalisco/CPA1/20 HAI assays as virus reagents were not
available.
Day 21 sera from unadjuvanted A(H7N9) VLP immunized
mice showed HAI antibody titers to all be >1:64 against the
homologous A/Anhui/1/2013 H7N9 virus (Fig. 2A). High anti HA
responses at all doses tested were likely due to being at the max-
imum end of the response curve in mice. Immunization with
VLP adjuvanted with 1.9 IU of ISCOMATRIX enhanced HAI anti-
body responses by 3- to 4-fold. As expected A/Anhui/1/2013
(H7N9)  VLP induced HAI responses against the closely related
with A/Shanghai/1/2013 (H7N9) (Fig. 2B) but also the heterolo-
gous H7N3 inﬂuenza A/chicken/Jalisco/CPA1/2012 (Fig. 2C). Levels
of cross-reactive HAI antibody were also enhanced 3- to 4-fold in
VLP formulated with ISCOMATRIX adjuvant. A quantitative com-
parison of HAI titers observed with homologous and heterologous
H7 is difﬁcult as homologous H7 was  presented on virus and het-
erologous H7 was presented on VLP. However, HAI titers were
similar between the two heterologous H7 VLP even though the H7
expressed by the A/chicken/Jalisco/CPA1/2012 (H7N3) VLP is more
divergent from A/Anhui/1/2013 H7 than is A/Shanghai/1/2013 H7.
Sera from mice immunized with unadjuvanted
A/chicken/Jalisco/CPA1/2012 (H7N3) VLP showed HAI antibody
titers of 1:32 when evaluated against the homologous A(H7N3)
VLP and when formulated with ISCOMATRIX HAI titers against
the A(H7N3) VLP were increased 2- to 4-fold (Fig. 2C). Sera were
also evaluated against virus or VLP expressing the heterologous
H7. For the 0.7 and 2 g dose of unadjuvanted A(H7N3) VLP, HAI
titers of 24 (p < 0.001) and 26 (p < 0.001) for the A/Anhui/1/2013
(H7N9) and 18 (p < 0.006) and 14 (p = 0.071) for A/Shanghai (H7N9)
VLP were observed. While these titers are low, three of the four
groups demonstrated signiﬁcant titers when compared to pre-
immunization sera. Just as the use of the ISCOMATRIX enhanced
the titers against the homologous H7, titers were also signiﬁcantly
enhanced against the heterologous H7 (Fig. 2A and C). GMTs
of 142, and 103 against A/Anhui/1/2013 (H7N9) and 56 and 56
for A/Shanghai (H7N9) VLP were observed for the 0.7 and 2 g
dose. The data again indicated the generation of cross-reactive H7
antibody and the enhancement of these responses by ISCOMATRIX
adjuvant.
While cross-reactivity was observed on heterologous H7 fol-
lowing immunization with either A(H7N9) or A(H7N3) VLPs,
no HAI responses were observed when sera was  tested on
A/Indonesia/05/2005 (H5N1) VLP (Fig. 2D). Similarly, no anti-
H7 reactivity was observed following immunization A/Indonesia
(H5N1) VLP indicating the expected strain speciﬁcity for the HAI
response (Fig. 2A, B and C). A(H5N1) VLP were immunogenic and
immunization with both 1 and 3 g induced HAI titers >1:64 and
responses were enhanced 4-fold in the presence of ISCOMATRIX
(Fig. 2D).The  induction of anti-NA antibodies were evaluated in a NI
assay using puriﬁed N9 neuraminidase. Sera from A/Anhui/1/2013
(H7N9) VLP immunized mice demonstrated good levels of NI
activity and immunization of A(H7N9) VLP with the ISCOMATRIX
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Fig. 1. (A) Diagram of inﬂuenza A/Anhui/1/2013 (H7N9) NA and HA and A/Indonesia/05/2005 (H5N1) M1 genes each under the transcriptional control at the 5′ of the AcMNPV
polyhedrin promoter (PolH) and 3′ polyadenylation (pA) signals. (B) SDS-PAGE and Comassie blue stained gel and Western blot analysis of A/Anhui/1/2013 (H7N9) NA, HA,
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LP.
esulted in a signiﬁcant enhancement in NI titers (Fig. 3). Antis-
ra from mice immunized with the A/chicken/Jalisco/CPA1/2012
H7N3)  or A/Indonesia/05/2005 (H5N1) VLP did induce detectable
I activity supporting the speciﬁcity of the NI assay, and conﬁrming
he expected lack of cross-reactivity between N9 and both N3 and
1.
.3. Protection of immunized mice against a lethal challenge with
/Anhui/1/2013 virus
Mice  immunized with A/inﬂuenza VLP on day 0 and 14 were
hallenged with 4.4 × 103 TCID50 pfu (3.6 × LD50) of infectious
/Anhui/1/2013 (H7N9) virus on day 22. Following challenge, mice
ere monitored for weight loss and survival. A subset of mice
rom each group was euthanized on day 3 post challenge, and
ung virus titers determined (Table 1). Viral load in the lungs of
he placebo group was 106.4 pfu. Immunization with 2 and 6 g
/H7N9 VLP either with or without ISCOMATRIX resulted in an
bsence of detectable lung virus as did immunization with 2 g
(H7N3) VLP with ISCOMATRIX. A single animal had a low titer
f virus at the 0.7 A/H7N9 antigen dose and the H7N3 induced an
verall 1 log10 reduction in viral titer. Immunization of mice with
(H5N1) VLP did not result in reduction in lung virus as expected mouse monoclonal anti A(H7N7), rabbit anti-universal conserved NA peptide, and
7N9) VLP. (D) Electron micrograph of negatively stained A/Anhui/1/2013 (H7N9)
from  the lack of cross reactive antibody observed in the HAI assay
(Fig. 2).
Following virus challenge, mice were monitored daily for weight
loss. Analysis of average percent weight loss on day 7 post challenge
indicated animals immunized with A(H7N9) and A(H7N3) VLP vac-
cines, irrespective of dose or adjuvant, had no signiﬁcant weight
loss (Table 2). However, mice in the control and A(H5N1) VLP vac-
cinated groups had reached or near the 25% weight loss where they
were euthanize (Table 2). As immunogenicity and lung viral titers
of mice within each vaccine formulation gave similar results irre-
spective of VLP dose, the weight loss and survival data combined of
mice immunized with either 0.7 and 2 for A(H7N9) and 0.7 and 2 g
for A(H7N3) VLP or 1 and 3 g for A/H5N1 groups were compared
in Fig. 4. Following virus challenge, mice were monitored daily for
weight loss (Fig. 4A). Weight loss was  observed by day 3 for mice
immunized with unadjuvanted A(H7N9) and A(H7N3) VLP as well
as both adjuvanted and unadjuvanted A(H5N1) VLP as well as the
placebo groups. Weight loss continued for the placebo group as
well as both A(H5N1) groups until they were euthanized on day 7
and 8 after becoming moribund, with a weight loss in excess of 25%
of their initial weight. Weight loss for the unadjuvanted A(H7N9)
and A(H7N3) groups stabilized on days 4–5 and weight gain was
observed on subsequent days. For mice immunized with either
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Vig. 2. Day 21 HAI responses in mice immunized with A/Anhui/1/2013 (H7N9), A/
gainst (A) A/Anhui/1/2013 (H7N9), (B) A/Shanghai/1/2013 (H7N9), (C) A/Chicken/J
(H7 N)9 or A(H7N3) VLP formulated with ISCOMATRIX, minimal
eight loss was observed on days 4–5 and they quickly returned
o normal. The resistance to severe weight loss following challenge
y mice immunized with A(H7N9) and A(H7N3) VLP formulated
ith ISCOMATRIX and the recovery observed for the unadjuvanted
(H7N9) and A(H7N3) groups corresponds to the anti-HA titers
bserved in the HAI assays.
As  indicated in Fig. 4B, 100% of mice immunized with A(H7N9)
nd A(H7N3) VLP survived the lethal virus challenge indicating
he protective efﬁcacy of homologous A(H7N9) and heterologous
(H7N3) VLP. The survival of mice immunized with the A(H7N3)
LP is attributed to the activity of HA antibody cross-reactive onesia/05/2005 (H5N1), or A/Chicken/Jalisco/CPA1/2012 (H7N3). Sera were analyzed
/CPA1/2012 (H7N3), and (D) A/Indonesia/5/2005 (H5N1) antigens.
heterologous  H7. While anti-NA antibodies are known to contribute
to the protective antibody response, the A(H7N3) VLP immunized
group did not exhibit detectable cross-reactive NA antibody. All
animals in the A(H5N1) groups as well as the placebo group exhib-
ited severe disease characterized by huddling, rufﬂed fur, lethargy,
anorexia leading to weight loss, and death (euthanasia at a humane
endpoint). Animals in these groups had to be euthanized as early
as 5 days post challenge and 100% of the animals were eutha-
nized by day 8. Mice in the unadjuvanted A(H7N9) and A(H7N3)
groups exhibited mild disease with some weight loss while those
immunized with VLP ± ISCOMATRIX exhibited no disease symp-
toms. Immunization with either A(H7N9) or A(H7N3) VLP conferred
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Fig. 3. Day 21 NI responses from mice immunized with A/Anhui/1/2013 (H7N9), A/Indon
and  day14 (boost). Graph shows NI titers of day 21 pre-challenge sera in a fetuin inhibitio
Table 1
Viral  recovery from lung tissue of mice challenged with A/Anhui/1/2013 (H7N9)
inﬂuenza.
Immunogena Dose (g) ISCOMATRIX Lung virus titerb
Log10 TCID50/gm tissue
None 0 + 6.4
A/H7N9 6 − <3.1
A/H7N9 2 − <3.1
A/H7N9 0.7 − 3.7
A/H7N9 2 + <3.1
A/H7N9 0.7 + <3.1
A/H7N3 2 − 5.0
A/H7N3 0.7 − N/Ac
A/H7N3 2 + <3.1
A/H7N3 0.7 + N/Ac
A/H5N1 3 − 6.1
A/H5N1 1 − 6.4
A/H5N1 3 + 6.3
A/H5N1 1 + 6.2
a Groups of 5 mice were immunized by intramuscular injection with A/inﬂuenza
VLP  as described in Section 2.7.
b Mice were challenged intranasally with 4.4 × 103 TCID50 pfu (3.6 × LD50)
A/Anhui/1/2013 virus eight days following the last immunization. Lung tissue was
harvested 3 days post challenge and viral titers in lung homogenates determined as
measured in Section 2.7 and represent the average of 3 animals.
c N/A – not available. Mice in these groups died <24 h of transfer to the challenge
facility  and thus were not added to either the lung virus or challenge data. Deaths
were  not attributed to either immunization or virus challenge.
Table 2
Percent change in body weight of mice challenged with A/Anhui/1/2013 (H7N9) inﬂuenz
Immunogena Dose (g) ISCOMATRIX N at day 1b
None 0 + 5 
A/H7N9  6 − 3 
A/H7N9  2 − 5 
A/H7N9  0.7 − 5 
A/H7N9  2 + 5 
A/H7N9  0.7 + 5 
A/H7N3  2 − 5 
A/H7N3  0.7 − 5 
A/H7N3  2 + 5 
A/H7N3  0.7 + 4 
A/H5N1  3 − 5 
A/H5N1  1 − 5 
A/H5N1  3 + 5 
A/H5N1  1 + 5 
a Mice were immunized by intramuscular injection with A/inﬂuenza VLP as described
A/Anhui/1/2013 virus eight days following the last immunization.
b In the two groups where N < 5 on day 1, mice died <24 h of transfer to the challenge fa
c wt. = weight in gm ± standard deviation.
d Number of mice surviving challenge on day 7.esia/05/2005 (H5N1) or A/chicken/Jalisco/CPA1/2012(H7N3) VLP on day 0 (prime)
n assay using puriﬁed A/Anhui/1/2013 (H7N9) NA as a source of neuraminidase.
signiﬁcant protection (p < 0.001) in pairwise comparisons of vac-
cine groups analyzed and estimated by least squares mean when
compared to placebo and immunization with A(H5N1) VLP vaccine.
4. Discussion
Following the announcement 31 March 2013 by the Govern-
ment of China notifying the World Health Organization (WHO) of
human infections with the avian inﬂuenza A(H7N9) virus [12] the
ﬁrst A(H7N9) sequences were reported [13]. In a previous human
study of an inactivated inﬂuenza avian inﬂuenza A(H7N7) vaccine
in man  [14], the immunogenicity of the H7 subtype vaccine was
poor suggesting that an A(H7N9) vaccine may  require a high dose
and likely an adjuvant or both to provide protection [2]. In addition,
studies with A(H5N1) vaccines have generally required 2 × 90 g
unadjuvanted or lower doses of adjuvanted vaccine to achieve ade-
quate levels of HAI antibodies in a majority of subjects. However,
mouse immunogenicity studies of recombinant inﬂuenza A(H5N1)
VLP vaccine were predictive of immunogenicity in man  [9,11].
Bright et al. [11] reported cross-clade protective immune response
of an A(H5N1) VLP vaccine in mice. That same A(H5N1) VLP vac-
cine was  subsequently shown to induce in humans cross-reactive
neutralizing antibodies that preferentially bind to an oligomeric
form of inﬂuenza HA [11]. The data here indicated that the A(H7N9)
VLP vaccine candidate was  immunogenic and protective against
a.
wt.c (gm) day 1 N at day 7d wt. at day 7 (% of day 1)
19.3 ± 0.7 3 74 ± 1
18.2 ± 0.8 3 99 ± 5
17.1 ± 1.1 5 98 ± 3
18.0 ± 0.8 5 98 ± 2
18.7 ± 1.3 5 101 ± 3
18.5 ± 0.9 5 101 ± 2
17.8 ± 0.9 5 98 ± 4
16.8 ± 1.2 5 98 ± 4
17.9 ± 1.3 5 104 ± 4
19.0 ± 1.1 5 104 ± 5
18.9 ± 1.1 4 74 ± 1
17.6 ± 0.9 3 78 ± 3
19.1 ± 0.8 1 75
18.1 ± 0.7 2 74 ± 1
 in Section 2.7 and challenged intranasally with 4.4 × 103 TCID50 pfu (3.6 × LD50)
cility and were not included in further analysis.
4312 G.E. Smith et al. / Vaccine 3
A.
B.
P
er
ce
nt
 S
ur
vi
va
l
Day Post Challenge 
100
90
80
70
60
50
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
H7N9 
H7N9 + ISCOMATRIX
H7N3 
H7N3 + ISCOMATRIX
H5N1 
H5N1 + ISCOMATRIX
Placebo 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
12
14
16
18
20
22
Days Post Challenge
W
ei
gh
t (
gr
am
s)
H7N3
H7N9
H7N9 + ISCOMATRIX
H5N1
H5N1 + ISCOMATRIX
H7N3 + ISCOMATRIX
Placebo
Fig. 4. Body weight (A) and percent survival (B) of mice immunized inﬂuenza
A
c
w
u
c
a
A
t
t
a
l
n
d
w
c
a
t
r
a
p
v
e
g
T
i
d
i
A
H
d
i
d
e
l
p
difﬁcult, quantiﬁcation of the HA content of the VLP given that(H7N9),  A(H7N3), and A(H5N1) VLPs with and without ISCOMATRIX adjuvant and
hallenged with a lethal dose A/Anhui/1/2013 (H7N9) virus.
ild type lethal viral challenge, even with less than a microgram of
nadjuvanted vaccine. Additionally, the A(H7N3) VLP vaccine was
ross-protective against a lethal challenge with A/Anhui/1/2013
nd produced cross reacting HAI to non-homologous A(H7N9).
(H5N1) VLPs were not protective against A(H7N9) virus argues
hat the protection in A(H7N3) immunized mice was  speciﬁc to
he HA and not due to baculovirus or other minor contaminants
s all VLPs in the study were puriﬁed in a similar manner and had
ow levels of baculovirus antigen contamination. However, it was
ot determined if VLP-induced protective immune responses were
ue to IgG or IgM or both, especially for A(H7N3) given that mice
ere challenged 8 days following a boost. Further studies including
hallenge of vaccinated mice at a later time point, antibody subclass
nalysis, duration of immunity, and identiﬁcation of protective epi-
opes are important. However, we consider this mouse model as a
easonable and rapid in vivo screening method as a preliminary
ssessment of vaccine efﬁcacy, and thus useful in responding to a
otential pandemic by providing animal protection data prior to
accinating humans.
The  addition of ISCOMATRIX to the A(H7N9) VLP further
nhanced the immunogenicity and efﬁcacy to both the homolo-
ous and non-homologous strains and may  provide dose sparing.
he current A(H7N3) highly pathogenic avian inﬂuenza outbreaks
n Jalisco, Mexico, with high numbers of infected animals in high-
ensity human populations pose a risk not just to the poultry
ndustry but of reassortants that could cause disease in humans.
n effective A(H7N9) vaccine that was cross-protective with other
7 subtypes would add an additional margin of safety to the unpre-
ictable nature of inﬂuenza pandemics.
Since 1997, avian inﬂuenza A viruses of various subtypes,
ncluding H5N1, H9N2, H7N7, H5N2, and now H7N9, have been
ocumented to infect and cause illness in humans. Of these, Morens
t al. [3] have noted the remarkable clinical-epidemiological simi-
arity between H7N9 and H5N1 has been the most striking, with a
ossibility that many humans appearing to have been exposed to1 (2013) 4305– 4313
both, yet without clinically apparent or immunologically detectable
evidence of infection. At the same time, disease in sporadic human
cases has been far more severe than in cases caused by any human-
adapted inﬂuenza A virus ever encountered (59% and 28% case
fatality rates, respectively), characterized by bilateral pneumonia
progressing to acute respiratory distress syndrome and multi-
organ failure. While there has fortunately been little or no evidence
of person-to-person transmission of either virus, the potential for
pandemic spread for a virus in which all 8 segments encode pro-
teins similar to the avian inﬂuenza A consensus sequence – such as
the 1918 pandemic virus – cannot be ignored [3].
In  view of the potential for pandemic spread of avian viruses,
government, academia and industry have devoted considerable
effort over the past decade toward the development and test-
ing of both traditional and novel manufacturing platforms for the
generation of pandemic vaccine candidates for either stockpiling
purposes (H5N1) or for actual deployment (H1N1 pdm09). The lat-
ter vaccines were based on the traditional inactivated split-virus or
subunit platforms, but were introduced too late and appeared to
have suboptimal clinical effectiveness (56%; 95% CI, 23%–75%) [2].
Adjuvanted forms of these vaccines were approved in Europe, and
were shown to substantially reduce the amount of antigen required
to achieve the currently accepted HAI antibody immune corre-
lates [15–17] and improve the vaccine effectiveness [18]. However,
none of these vaccines have taken an approach toward broaden-
ing the immune response, whether by attempting to elicit anti-NA
antibody or to enhance T cell responses to reduce the severity
of inﬂuenza disease (symptomology and virus shedding) in the
absence of a sufﬁciently robust neutralizing antibody response.
Previous  studies of our VLP candidates in animals and humans
indicate that an inﬂuenza vaccine platform designed to present
both full-length HA and NA antigens in VLP form may  better emu-
late native presentation of these antigens to the immune system,
yet at the same time avoid the safety concerns posed by a live,
replicating agent. Because of their particulate nature, uptake of
VLP by antigen-presenting cells may  not only result in presenta-
tion of peptides with major histocompatibility complex II (MHC-II)
molecules and stimulation of humoral immunity, but may  also
result in cross-presentation of peptides with MHC-I molecules for
activation of cytotoxic T-lymphocytes (CTLs) [19]. In addition, the
repetitive nature of the HA and NA on the VLP surface may  stim-
ulate humoral immune responses directly in the lymph nodes
and also have the potential for limiting spread of virus distally
to the lower airways. Finally, it is also possible that conserved
T-cell epitopes on the HA and M1  proteins may  induce cell-
mediated immune responses that reduce the severity of inﬂuenza
disease.
Of the ﬁrst three published sequences of A(H7N9) that
were reported A/Anhui/1/2013 and A/Shanghai/1/2013 were phy-
logenetically distinct with 8 amino acid difference in their
hemagglutinin gene sequences and A/Anhui/1/2013 was recom-
mended as a vaccine strain due to high titers when grown in
embryonated hens eggs [13]. We  choose to clone and produce
both A/Anhui/1/2013 and A/Shanghai/1/2013 strain A(H7N9) VLP
but to focus vaccine development on the former as recommended.
The two unique HA and A(H7N9) NA genes were codon opti-
mized, synthesized, baculovirus expression vectors constructed
and conﬁrmed to contain the genes with the correct sequences.
A/Anhui/1/2013 and A/Shanghai/1/2013 VLP as well as individual
A/Anhui/1/2013 HA and NA antigens were produced and puri-
ﬁed. At this stage there were two signiﬁcant challenges; ﬁrst was
positive identiﬁcation of A(H7N9) antigens, and second and moreweeks were needed before speciﬁc HA antibody could be made
in sheep for use in a conventional single radial immunodiffusion
(SRID) assay for inﬂuenza vaccine potency.
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Identiﬁcation of A/Anhui/1/2013 HA was performed using West-
rn blot and a mouse monoclonal antibody against another H7
ubtype inﬂuenza A(H7N7). A/Anhui/1/2013 NA was identiﬁed
ith antibody against a conserved peptide [20] which reacted with
ll of the A strain NAs in A(H7N9), A(H7N3) and A(H5N1) VLP. The
mino acid peptide sequences of A/Anhui/1/2013 HA and NA were
lso analyzed using LC–MS, conﬁrming their identity.
However, this uncovered another challenge in that A(H7H9) NA
nd A(H7N3) NA essentially co-migrated with respective H7 HAs.
canning densitometry of SDS-PAGE gels initially overestimated
he HA content, thus the dose, of A(H7N9) and A(H7N3) VLP used
n the mouse challenge study. Capillary gel electrophoresis is a
idely used method for the determination of protein purity and
ffers greater resolution and more reproducible quantitation com-
ared with that of SDS-PAGE. After deglycosylation, A(H7N9) HA
nd NA were separated and a more accurate measure of HA could
e determined, thus adjustments were made to doses of A(H7N9)
nd A(H7N3) VLP used in the mouse challenge study.
The  current study provides further support for the potential gen-
ration of desirable attributes [21] that could result in a safe and
ffective H7N9 vaccine candidate. First, the immunogenicity and
fﬁcacy of 2 doses of A/Anhui/1/2013 (H7N9)-VLP vaccine candi-
ate administered on study days 0 and 14 were clearly established
n the lethal challenge Balb/c mouse model, the most widely used
nimal model for inﬂuenza virus research. In experiments eval-
ating highly pathogenic strains such as H5 and H7, a lethal dose
ypically results in severe disease characterized by huddling, rufﬂed
ur, lethargy, anorexia leading to weight loss, and death (euthana-
ia at a humane endpoint) and therefore provides an unambiguous
est of a vaccine candidate. In our study, all 25 mice in the H5N1
LP and placebo groups required euthanasia within 8 days after
hallenge, compared with none in the H7N9 VLP vaccine groups.
rotection from death was correlated with both robust HAI and
ntigen-speciﬁc anti-NA antibody responses following vaccination,
either of which were elicited in the two control groups, along with
vidence of cross-protective HAI responses following vaccination
ith both H7-based candidates.
It  remains to be seen whether an A/Anhui/1/2013-like (H7N9)
r a similar pathogen will emerge into the broader population but
rospective development of an immunogenic and cross-protective
7N9 vaccine is a prudent public health measure and the insect
ell-derived A(H7N9) VLP vaccine with or without a saponin-based
djuvant for dose sparing to be considered as candidate pandemic
accine. This study represents a promising approach to provide a
accine for an emerging lethal pandemic inﬂuenza virus. Based on
hese positive and unambiguous results, further studies in humans
nd other animal models were warranted and an H7N9 VLP vaccine
andidate described in the report is in clinical testing [22].
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